AR, androgen receptor, 367

N. diseases: 854; N. variants: 163
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0699885
Disease: Carcinoma of bladder
Carcinoma of bladder
0.100 Biomarker disease BEFREE Our findings implicate the involvement of both androgens and the AR in bladder cancer. 17406000 2007
CUI: C0699885
Disease: Carcinoma of bladder
Carcinoma of bladder
0.100 GeneticVariation disease BEFREE CAG repeats in the androgen receptor gene are shorter in patients with pulmonary, esophageal or bladder carcinoma and longer in women with uterine leiomyoma. 20127024 2010
CUI: C0699885
Disease: Carcinoma of bladder
Carcinoma of bladder
0.100 Biomarker disease BEFREE Antitumor effects of bladder cancer-specific adenovirus carrying E1A-androgen receptor in bladder cancer. 22218302 2012
CUI: C0699885
Disease: Carcinoma of bladder
Carcinoma of bladder
0.100 Biomarker disease BEFREE The role of androgen receptor in cell growth and drug sensitivity was also evaluated in vitro and in vivo in several bladder cancer cell lines. 22608749 2012
CUI: C0699885
Disease: Carcinoma of bladder
Carcinoma of bladder
0.100 Biomarker disease BEFREE However, crosstalk between AR and EGFR pathways in bladder cancer remains uncharacterized. 22922989 2012
CUI: C0699885
Disease: Carcinoma of bladder
Carcinoma of bladder
0.100 Biomarker disease BEFREE Determination of the AR status in cystectomy specimens offers new therapeutic approaches in locally advanced bladder cancer. 23330817 2013
CUI: C0699885
Disease: Carcinoma of bladder
Carcinoma of bladder
0.100 Biomarker disease BEFREE We then assessed the effects of androgen on β-catenin in AR-positive and AR-negative bladder cancer cell lines. 23447569 2013
CUI: C0699885
Disease: Carcinoma of bladder
Carcinoma of bladder
0.100 Biomarker disease BEFREE Collectively, our results indicate that EGF may be able to potentiate AR transactivation that leads to enhancing BCa progression, which may help us to develop a better therapeutic approach to treat BCa via targeting both EGF and AR signaling. 24126741 2013
CUI: C0699885
Disease: Carcinoma of bladder
Carcinoma of bladder
0.100 AlteredExpression disease BEFREE It is concluded that suppression of AR expression decreased the production of TGF-β, inhibiting EMT and bladder cancer cell growth in vitro and in vivo, implying that its use might be a potential therapeutic target for the treatment of bladder cancer. 24329492 2014
CUI: C0699885
Disease: Carcinoma of bladder
Carcinoma of bladder
0.100 Biomarker disease BEFREE Activated androgen receptor promotes bladder cancer metastasis via Slug mediated epithelial-mesenchymal transition. 24662746 2014
CUI: C0699885
Disease: Carcinoma of bladder
Carcinoma of bladder
0.100 AlteredExpression disease BEFREE We discuss work demonstrating AR expression in bladder cancer and its role in promoting formation and progression of tumors. 26229034 2015
CUI: C0699885
Disease: Carcinoma of bladder
Carcinoma of bladder
0.100 Biomarker disease BEFREE Recent studies suggest that the androgen receptor (AR) might play important roles in influencing bladder cancer progression, yet its clinical application remains unclear. 26264279 2015
CUI: C0699885
Disease: Carcinoma of bladder
Carcinoma of bladder
0.100 AlteredExpression disease BEFREE Importantly, ELK1 appears to require activated AR to regulate bladder cancer cell proliferation, but not cell migration. 26342199 2015
CUI: C0699885
Disease: Carcinoma of bladder
Carcinoma of bladder
0.100 GeneticVariation disease BEFREE Conditional Expression of the Androgen Receptor Increases Susceptibility of Bladder Cancer in Mice. 26862755 2016
CUI: C0699885
Disease: Carcinoma of bladder
Carcinoma of bladder
0.100 Biomarker disease BEFREE Finally, in vivo mouse models of xenografted bladder cancer T24 cells with CD4(+) T cells confirmed in vitro coculture studies and concluded that infiltrating CD4(+) T cells can promote bladder cancer metastasis via modulation of the IL1→AR→HIF1α→VEGFa signaling. 27196763 2016
CUI: C0699885
Disease: Carcinoma of bladder
Carcinoma of bladder
0.100 Biomarker disease BEFREE Thiazolyl blue cell viability assay, flow cytometry, scratch wound-healing assay, transwell invasion assay, real-time polymerase chain reaction, and reporter gene assay were performed in AR-positive (e.g., UMUC3, TCCSUP, and 647V-AR) and AR-negative (e.g., UMUC3-AR-short hairpin RNA [shRNA], TCCSUP-AR-shRNA, 647V) bladder cancer lines treated with dihydrotestosterone and each AR antagonist. 27330033 2016
CUI: C0699885
Disease: Carcinoma of bladder
Carcinoma of bladder
0.100 AlteredExpression disease BEFREE Our results suggest that enzalutamide may have the potential to treat patients with advanced gemcitabine-resistant bladder cancer with increased AR expression. 27909718 2017
CUI: C0699885
Disease: Carcinoma of bladder
Carcinoma of bladder
0.100 Biomarker disease BEFREE Areas covered: We summarize and discuss available data suggesting the involvement of AR and its potential downstream targets in the development and progression of bladder cancer. 28064545 2017
CUI: C0699885
Disease: Carcinoma of bladder
Carcinoma of bladder
0.100 Biomarker disease BEFREE In particular, androgen-mediated androgen receptor signals have been shown to correlate with the promotion of tumor development and progression, which may clearly explain some sex-specific differences in bladder cancer. 28241422 2017
CUI: C0699885
Disease: Carcinoma of bladder
Carcinoma of bladder
0.100 Biomarker disease BEFREE Given that the androgen receptor (AR) has been discussed as a possible factor in the development and progression of bladder cancer, we investigated the predictive value of AR in stage pT1 NMIBC. 28342317 2017
CUI: C0699885
Disease: Carcinoma of bladder
Carcinoma of bladder
0.100 AlteredExpression disease BEFREE We therefore conducted this meta-analysis to assess the clinicopathological impact of the expression of androgen receptor (AR) and estrogen receptors (ERs) in bladder cancer. 28362839 2017
CUI: C0699885
Disease: Carcinoma of bladder
Carcinoma of bladder
0.100 Biomarker disease BEFREE The correlations of miR-124 with XIST and AR in bladder cancer samples were statistically analyzed. 28869948 2017
CUI: C0699885
Disease: Carcinoma of bladder
Carcinoma of bladder
0.100 Biomarker disease BEFREE Emerging preclinical evidence suggests the critical role of androgen-mediated androgen receptor (AR) signals in the development of bladder cancer. 29119053 2017
CUI: C0699885
Disease: Carcinoma of bladder
Carcinoma of bladder
0.100 Biomarker disease BEFREE NF-κB activators and inhibitors also significantly induced and reduced, respectively, cell proliferation/migration/invasion of AR-positive bladder cancer lines, but not AR-knockdown or AR-negative lines, and their growth in xenograft-bearing mice. 29592878 2018
CUI: C0699885
Disease: Carcinoma of bladder
Carcinoma of bladder
0.100 Biomarker disease BEFREE Androgen Receptor Is Inactivated and Degraded in Bladder Cancer Cells by Phenyl Glucosamine via miR-449a Restoration. 29659560 2018